Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com
FDA Grants Breakthrough Therapy Designation to TAR-200 for BCG-Unresponsive High-Risk NMIBC
January 5th 2024The FDA has granted breakthrough therapy designation to TAR-200 for use in the treatment of patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer who are not candidates for or opted not to receive radical cystectomy.
Read More
LUMINANCE Data Support the Frontline Use of Durvalumab Plus Platinum/Etoposide in ES-SCLC
January 4th 2024The safety and efficacy data observed with the administration of 5 or more cycles of induction platinum/etoposide and concurrent durvalumab in patients with extensive-stage small cell lung cancer enrolled in the phase 3b LUMINANCE study aligned with outcomes reported in the phase 3 CASPIAN trial.
Read More
FDA Grants Fast Track, Breakthrough Therapy Designations to Cretostimogene Grenadenorepvec for NMIBC
January 3rd 2024The FDA has granted fast track and breakthrough therapy designations to cretostimogene grenadenorepvec for use as a potential therapeutic option in patients with high-risk BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 tumors.
Read More
Vibostolimab Plus Pembrolizumab Coformulation ± Docetaxel Did Not Significantly Improve PFS in NSCLC
January 3rd 2024A coformulation of vibostolimab and pembrolizumab with or without docetaxel failed to result in a statistically significant improvement in progression-free survival compared with docetaxel alone in patients with metastatic non–small cell lung cancer.
Read More